Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Visvanathan S, Daniluk S, Ptaszyński R, Müller-Ladner U, Ramanujam M, Rosenstock B, Eleftheraki AG, Vinisko R, Petříková A, Kellner H, Dokoupilova E, Kwiatkowska B, Alten R, Schwabe C, Baum P, Joseph D, Fine JS, Padula SJ, Steffgen J.

Ann Rheum Dis. 2019 Jun;78(6):754-760. doi: 10.1136/annrheumdis-2018-214729. Epub 2019 Mar 22.

2.

Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.

Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, Kleiner O, Fuentes-Duculan J, Garcet S, Davis JW, Grebe KM, Fine JS, Padula SJ, Krueger JG.

J Allergy Clin Immunol. 2019 Jun;143(6):2158-2169. doi: 10.1016/j.jaci.2018.11.042. Epub 2018 Dec 20.

3.

BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.

Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.

Clin Immunol. 2018 Dec;197:205-218. doi: 10.1016/j.clim.2018.10.008. Epub 2018 Oct 16.

PMID:
30339790
4.

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.

Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J.

J Crohns Colitis. 2018 Nov 9;12(10):1170-1179. doi: 10.1093/ecco-jcc/jjy099.

5.

Ambient Pollution-related Reprogramming of the Human Small Airway Epithelial Transcriptome.

O'Beirne SL, Shenoy SA, Salit J, Strulovici-Barel Y, Kaner RJ, Visvanathan S, Fine JS, Mezey JG, Crystal RG.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1413-1422. doi: 10.1164/rccm.201712-2526OC.

PMID:
29897792
6.

Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.

Chalmers SA, Wen J, Doerner J, Stock A, Cuda CM, Makinde HM, Perlman H, Bosanac T, Webb D, Nabozny G, Fine JS, Klein E, Ramanujam M, Putterman C.

Arthritis Res Ther. 2018 Jan 25;20(1):10. doi: 10.1186/s13075-017-1500-0.

7.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Ganesan R, Raymond EL, Mennerich D, Woska JR Jr, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D, Jerath K, Truncali K, Frego L, Sepulveda E, Gupta P, Brown SE, Howell MD, Canada KA, Kroe-Barrett R, Fine JS, Singh S, Mbow ML.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

8.

Barriers to discharge from inpatient rehabilitation: a teamwork approach.

Cruz LC, Fine JS, Nori S.

Int J Health Care Qual Assur. 2017 Mar 13;30(2):137-147. doi: 10.1108/IJHCQA-07-2016-0102.

PMID:
28256931
9.

Poster 170 A Rare Case of Radical Mastectomy with Extensive Debridement Due to Necrotizing Fasciitis Leading to Unanticipated Functional Compromise: A Case Report.

Cruz LC, Abrams S, Fine JS, Nori S.

PM R. 2016 Sep;8(9S):S217. doi: 10.1016/j.pmrj.2016.07.210. Epub 2016 Sep 24. No abstract available.

PMID:
27672936
10.

Persistence of circulating endothelial microparticles in COPD despite smoking cessation.

Strulovici-Barel Y, Staudt MR, Krause A, Gordon C, Tilley AE, Harvey BG, Kaner RJ, Hollmann C, Mezey JG, Bitter H, Pillai SG, Hilton H, Wolff G, Stevenson CS, Visvanathan S, Fine JS, Crystal RG.

Thorax. 2016 Dec;71(12):1137-1144. doi: 10.1136/thoraxjnl-2015-208274. Epub 2016 Jul 26.

11.

Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.

Chalmers SA, Doerner J, Bosanac T, Khalil S, Smith D, Harcken C, Dimock J, Der E, Herlitz L, Webb D, Seccareccia E, Feng D, Fine JS, Ramanujam M, Klein E, Putterman C.

Sci Rep. 2016 May 19;6:26164. doi: 10.1038/srep26164.

12.

Persistence of smoking-induced dysregulation of miRNA expression in the small airway epithelium despite smoking cessation.

Wang G, Wang R, Strulovici-Barel Y, Salit J, Staudt MR, Ahmed J, Tilley AE, Yee-Levin J, Hollmann C, Harvey BG, Kaner RJ, Mezey JG, Sridhar S, Pillai SG, Hilton H, Wolff G, Bitter H, Visvanathan S, Fine JS, Stevenson CS, Crystal RG.

PLoS One. 2015 Apr 17;10(4):e0120824. doi: 10.1371/journal.pone.0120824. eCollection 2015.

13.

Pediatric fatality review of the 2013 National Poison Database System (NPDS): focus on intent.

Lowry JA, Fine JS, Calello DP, Marcus SM.

Clin Toxicol (Phila). 2015 Feb;53(2):79-81. doi: 10.3109/15563650.2014.996292. Epub 2015 Jan 8. Review. No abstract available.

PMID:
25567685
14.

Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.

Hartkamp LM, Fine JS, van Es IE, Tang MW, Smith M, Woods J, Narula S, DeMartino J, Tak PP, Reedquist KA.

Ann Rheum Dis. 2015 Aug;74(8):1603-11. doi: 10.1136/annrheumdis-2013-204143. Epub 2014 Apr 24.

PMID:
24764451
15.

2012 pediatric fatality review of the National Poison Database System.

Calello DP, Fine JS, Marcus SM, Lowry JA.

Clin Toxicol (Phila). 2014 Feb;52(2):93-5. doi: 10.3109/15563650.2013.878948. Epub 2014 Jan 30. Review. No abstract available.

PMID:
24476045
16.

Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.

Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, Burns L, Renteria L, Woods J, Chen L, Allard J, Ravindran P, Bitter H, Liang Z, Hogaboam CM, Kitson C, Budd DC, Fine JS, Bauer CM, Stevenson CS.

PLoS One. 2013;8(4):e59348. doi: 10.1371/journal.pone.0059348. Epub 2013 Apr 2.

17.

House dust mite models: will they translate clinically as a superior model of asthma?

Phillips JE, Peng R, Harris P, Burns L, Renteria L, Lundblad LK, Fine JS, Bauer CM, Stevenson CS.

J Allergy Clin Immunol. 2013 Jul;132(1):242-4. doi: 10.1016/j.jaci.2012.12.1571. Epub 2013 Feb 10. No abstract available.

PMID:
23403050
18.

2011 Pediatric fatality review of the National Poison Data System [corrected].

Fine JS, Calello DP, Marcus SM, Lowry JA.

Clin Toxicol (Phila). 2012 Dec;50(10):872-4. doi: 10.3109/15563650.2012.752494. Epub 2012 Dec 11. No abstract available. Erratum in: Clin Toxicol (Phila). 2013 Feb;51(2):124.

PMID:
23228006
19.

Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD.

Harris P, Sridhar S, Peng R, Phillips JE, Cohn RG, Burns L, Woods J, Ramanujam M, Loubeau M, Tyagi G, Allard J, Burczynski M, Ravindran P, Cheng D, Bitter H, Fine JS, Bauer CM, Stevenson CS.

Mucosal Immunol. 2013 May;6(3):474-84. doi: 10.1038/mi.2012.86. Epub 2012 Sep 19.

20.

Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, Müller KC, Holz O, Magnussen H, Watz H, Fine JS.

PLoS One. 2012;7(6):e38629. doi: 10.1371/journal.pone.0038629. Epub 2012 Jun 12.

21.

Patient safety at handoff in rehabilitation medicine.

Siefferman JW, Lin E, Fine JS.

Phys Med Rehabil Clin N Am. 2012 May;23(2):241-57. doi: 10.1016/j.pmr.2012.02.003. Epub 2012 Mar 17. Review.

PMID:
22537691
22.

Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions.

Teunissen MB, Zheng L, de Groot M, de Rie MA, Fine JS, Chen SC.

Arch Dermatol Res. 2012 Aug;304(6):443-9. doi: 10.1007/s00403-012-1231-7. Epub 2012 Mar 22.

23.

Lower extremity weakness after childbirth: a case of preserved nerve conduction studies, axonal involvement, and good recovery.

Nutini DN, Fine JS.

PM R. 2012 Jan;4(1):81-3. doi: 10.1016/j.pmrj.2011.10.012. No abstract available.

PMID:
22269458
24.

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.

Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, Rosenblum S, Kozlowski J, Fine JS, Zavodny PJ, Lundell D.

BMC Immunol. 2012 Jan 10;13:2. doi: 10.1186/1471-2172-13-2.

25.

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O'Mahony A, Owens TD, Lou Y, Hill RJ, Narula S, DeMartino J, Fine JS.

J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. doi: 10.1124/jpet.111.187740. Epub 2012 Jan 6.

PMID:
22228807
26.

Bleomycin induced lung fibrosis increases work of breathing in the mouse.

Phillips JE, Peng R, Burns L, Harris P, Garrido R, Tyagi G, Fine JS, Stevenson CS.

Pulm Pharmacol Ther. 2012 Aug;25(4):281-5. doi: 10.1016/j.pupt.2011.10.001. Epub 2011 Oct 20.

PMID:
22024054
27.

Targeting CXCR3 reduces ligand-induced T-cell activation but not development of lung allergic responses.

Shin YS, Takeda K, Ohnishi H, Jia Y, Shiraishi Y, Cox ML, Fine JS, Rosenblum S, Lundel D, Jenh CH, Manfra DJ, Gelfand EW.

Ann Allergy Asthma Immunol. 2011 Aug;107(2):145-53. doi: 10.1016/j.anai.2011.04.013. Epub 2011 Jun 12.

PMID:
21802023
28.

HOPE-BAL: improved molecular diagnostics by application of a novel technique for fixation and paraffin embedding.

Marwitz S, Abdullah M, Vock C, Fine JS, Visvanathan S, Gaede KI, Hauber HP, Zabel P, Goldmann T.

J Histochem Cytochem. 2011 Jun;59(6):601-14. doi: 10.1369/0022155411404417. Epub 2011 Mar 23.

29.

Inflammatory Signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice.

Stanton MC, Chen SC, Jackson JV, Rojas-Triana A, Kinsley D, Cui L, Fine JS, Greenfeder S, Bober LA, Jenh CH.

J Inflamm (Lond). 2011 Mar 16;8:8. doi: 10.1186/1476-9255-8-8.

30.

Drug-induced hemolytic anemia and thrombocytopenia associated with alterations of cell membrane lipids and acanthocyte formation.

Poulet FM, Penraat K, Collins N, Evans E, Thackaberry E, Manfra D, Engstrom L, Geissler R, Geraci-Erck M, Frugone C, Abutarif M, Fine JS, Peterson BL, Cummings BS, Johnson RC.

Toxicol Pathol. 2010 Oct;38(6):907-22. doi: 10.1177/0192623310378865. Epub 2010 Aug 30.

PMID:
20805317
31.

Kinetic assessment and therapeutic modulation of metabolic and inflammatory profiles in mice on a high-fat and cholesterol diet.

Engstrom LW, Bober L, Chen SC, Fine JS, Li Y, Stanton MC, Kinsley D, Cui L, Jackson JV, Rojas-Triana A, Lundell D, Laverty M, Gustafson EL, Jenh CH, Kowalski TJ, Manfra DJ.

PPAR Res. 2010;2010:970164. doi: 10.1155/2010/970164. Epub 2010 Apr 22.

32.

Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.

Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, Fine JS, Grant EP.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):1080-6. doi: 10.1016/j.bbrc.2009.12.025. Epub 2009 Dec 14.

PMID:
20004647
33.

CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis.

Wang Y, Cui L, Gonsiorek W, Min SH, Anilkumar G, Rosenblum S, Kozlowski J, Lundell D, Fine JS, Grant EP.

J Inflamm (Lond). 2009 Nov 11;6:32. doi: 10.1186/1476-9255-6-32.

34.

Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: role for p38 kinase.

Engstrom L, Pinzon-Ortiz MC, Li Y, Chen SC, Kinsley D, Nelissen R, Fine JS, Mihara K, Manfra D.

Int Immunopharmacol. 2009 Sep;9(10):1218-27. doi: 10.1016/j.intimp.2009.07.003. Epub 2009 Jul 16.

PMID:
19616132
35.

Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions.

Chen SC, de Groot M, Kinsley D, Laverty M, McClanahan T, Arreaza M, Gustafson EL, Teunissen MB, de Rie MA, Fine JS, Kraan M.

Arch Dermatol Res. 2010 Mar;302(2):113-23. doi: 10.1007/s00403-009-0966-2. Epub 2009 Jun 11.

PMID:
19517126
36.

Nmur1-/- mice are not protected from cutaneous inflammation.

Abbondanzo SJ, Manfra DJ, Chen SC, Pinzon-Ortiz M, Sun Y, Phillips JE, Laverty M, Vassileva G, Hu W, Yang S, Gustafson EL, Fine JS, Hedrick JA.

Biochem Biophys Res Commun. 2009 Jan 23;378(4):777-82. doi: 10.1016/j.bbrc.2008.11.148. Epub 2008 Dec 12.

PMID:
19070594
37.

CXCR2 antagonists for the treatment of pulmonary disease.

Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS.

Pharmacol Ther. 2009 Jan;121(1):55-68. doi: 10.1016/j.pharmthera.2008.10.005. Epub 2008 Oct 31. Review.

PMID:
19026683
38.

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L.

Br J Pharmacol. 2008 Jan;153(2):226-39. Epub 2007 Oct 1. Review.

39.

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.

Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, Gonsiorek W, Billah MM, Fine JS, Hey JA.

J Pharmacol Exp Ther. 2007 Aug;322(2):486-93. Epub 2007 May 11.

PMID:
17496165
40.

Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.

Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J, Lunn CA, Kozlowski JA, Lavey B, Piwinski J, Narula SK, Lundell DJ, Hipkin RW.

J Biol Chem. 2006 Sep 22;281(38):28143-51. Epub 2006 Jun 5.

41.

A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.

Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA.

J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. Epub 2005 Oct 28.

PMID:
16258021
42.

Factors affecting urinary myoglobin stability in vitro.

Chen-Levy Z, Wener MH, Toivola B, Daum P, Reyes M, Fine JS.

Am J Clin Pathol. 2005 Mar;123(3):432-8.

PMID:
15716240
43.

The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys.

Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM.

Toxicol Pathol. 2004 May-Jun;32(3):295-308.

PMID:
15204971
44.

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.

Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM.

J Biol Chem. 2004 Mar 26;279(13):12876-82. Epub 2004 Jan 6.

45.

Impairment of leukocyte trafficking in a murine pleuritis model by IL-4 and IL-10.

Fine JS, Rojas-Triana A, Jackson JV, Engstrom LW, Deno GS, Lundell DJ, Bober LA.

Inflammation. 2003 Aug;27(4):161-74.

PMID:
14527170
46.
47.

Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta.

Chou CC, Fine JS, Pugliese-Sivo C, Gonsiorek W, Davies L, Deno G, Petro M, Schwarz M, Zavodny PJ, Hipkin RW.

Br J Pharmacol. 2002 Nov;137(5):663-75.

48.

Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis.

Fine JS, Byrnes HD, Zavodny PJ, Hipkin RW.

Inflammation. 2001 Apr;25(2):61-7.

PMID:
11321360
49.

Evaluation of chemokine- and phlogistin-mediated leukocyte chemotaxis using an in vivo sponge model.

Fine JS, Jackson JV, Rojas-Triana A, Bober LA.

Inflammation. 2000 Aug;24(4):331-46.

PMID:
10850855
50.

Iron poisoning.

Fine JS.

Curr Probl Pediatr. 2000 Mar;30(3):71-90. Review. No abstract available.

PMID:
10742921

Supplemental Content

Support Center